- Home
- EQ vs IPW Comparison
EQ vs IPW Comparison
Compare EQ & IPW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- IPW
- Stock Information
- Founded
- EQ 2017
- IPW 2018
- Country
- EQ United States
- IPW United States
- Employees
- EQ N/A
- IPW N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- IPW Catalog/Specialty Distribution
- Sector
- EQ Health Care
- IPW Consumer Discretionary
- Exchange
- EQ Nasdaq
- IPW Nasdaq
- Market Cap
- EQ 24.8M
- IPW 29.3M
- IPO Year
- EQ 2018
- IPW 2021
- Fundamental
- Price
- EQ $0.59
- IPW $0.86
- Analyst Decision
- EQ Buy
- IPW Strong Buy
- Analyst Count
- EQ 2
- IPW 1
- Target Price
- EQ $5.00
- IPW $2.75
- AVG Volume (30 Days)
- EQ 117.7K
- IPW 197.8K
- Earning Date
- EQ 11-13-2024
- IPW 02-12-2025
- Dividend Yield
- EQ N/A
- IPW N/A
- EPS Growth
- EQ N/A
- IPW N/A
- EPS
- EQ N/A
- IPW N/A
- Revenue
- EQ $45,914,000.00
- IPW $78,571,632.00
- Revenue This Year
- EQ $4.76
- IPW $8.31
- Revenue Next Year
- EQ N/A
- IPW $77.15
- P/E Ratio
- EQ N/A
- IPW N/A
- Revenue Growth
- EQ 7.70
- IPW N/A
- 52 Week Low
- EQ $0.56
- IPW $0.40
- 52 Week High
- EQ $3.25
- IPW $3.65
- Technical
- Relative Strength Index (RSI)
- EQ 31.96
- IPW 44.81
- Support Level
- EQ $0.56
- IPW $0.78
- Resistance Level
- EQ $0.67
- IPW $1.02
- Average True Range (ATR)
- EQ 0.05
- IPW 0.12
- MACD
- EQ -0.01
- IPW 0.02
- Stochastic Oscillator
- EQ 10.53
- IPW 32.78
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
About IPW iPower Inc.
iPower Inc is online hydroponic equipment and accessory retailer and supplier in North America. The company sells products through own website as well as online channel partners that include Amazon, Walmart, and eBay.